Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Serum neurofilament light chain (NfL)and CSF glial fibrillary acidic protein (GFAP) together improve the prediction of long-term clinical outcomes in multiple sclerosis

              Author:Thebault, Simon   Fereshtehnejad, Seyed Mohammad   Bergman, Hailey   Bose, Gauruv   Freedman, Mark   

              Session Name:S9: MS Biomarkers, Immunology, and Basic Science  

              Topic:MS and Inflammatory Disease  

              Program Number:S9.001  

              Author Institution:University of Pennsylvania, Ottawa, ON, Canada  University of Ottawa, Ottawa, ON, Canada  

              Low Disease Activity Over 4 Years of Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis; the Phase IIIb ENSEMBLE Study

              Author:Bermel, Robert   Hartung, Hans-Peter   Brochet, Bruno   Benedict, Ralph   Berger, Thomas   Carroll, William   Vollmer, Timothy   Holmoy, Trygve   Karabudak, Rana   Killestein, Joep   Nos, Carlos   Patti, Francesco   Perrin Ross, Amy   Vanopdenbosch, Ludo   Wuerfel, Jens   Kuenzel, Thomas   Kadner, Karen   Kulyk, Inessa   Freedman, Mark   

              Session Name:S46: MS Therapeutics and Clinical Decision Making  

              Topic:MS and Inflammatory Disease  

              Program Number:S46.004  

              Author Institution:Mellen Center for MS, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Deptartment of Neurology, Heinrich-Heine-University Düsseldorf, Germany, Dusseldorf, Germany  Université de Bordeaux, Neurocentre Magendie INSERM, Bordeaux, France, Bordeaux, France  Jacobs School of Medicine and Biomedical Sciences, Department of Neurology, University of Buffalo, NY, USA, Buffalo, NY  Dept. of Neurology, Medical University of Vienna, Vienna, Austria  Department of Neurology, Sir Charles Gairdner Hospital, Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia, Subiaco, Australia  Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  Department of Neurology, Akershus University Hospital, Lørenskog, Norway, Lasker, Norway  Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey, Ankara, Turkey  Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, Amsterdam, Netherlands  Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, Barcelona, Spain, Barcelona, Spain  Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Catania, Italy, Catania, Italy  Loyola University Chicago, Chicago, IL, USA, Oak Brook, IL  Department of Neurology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Brugge, Belgium  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute Ottawa, ON, Canada., Ottawa, ON, Canada  

              Pregnancy Outcomes and Disease Course in NMOSD and MOGAD in CANOPTICS

              Author:Chu, Laura   Rotstein, Dalia   Freedman, Mark   Konig, Andrea   Lee, Liesly   Marrie, Ruth-Ann   McCombe, Jennifer   Morrow, Sarah   Parks, Natalie   Smyth, Penelope   Krysko, Kristen   

              Session Name:N2: Neuroscience in the Clinic: What Should a Neurologist Know About Pregnancy and Lactation?  

              Topic:MS and Inflammatory Disease  

              Program Number:N2.002  

              Author Institution:St. Michael's Hospital, Toronto, ON, Canada  University of Ottawa, Ottawa, ON, Canada  Sunnybrook Health Sciences Centre, Toronto, ON, Canada  University of Manitoba, Winnipeg, MB, Canada  University of Alberta, Edmonton, AB, Canada  London Health Sciences Centre, London, ON, Canada  Dalhousie University, Halifax, NS, Canada  

              Serum metabolic profile in early multiple sclerosis as predictor of long-term disease progression in BENEFIT

              Author:Cortese, Marianna   Peng, Xiaojing   Bjornevik, Kjetil   Clish, Clary B.   Edan, Gilles   Freedman, Mark   Hartung, Hans-Peter   Montalban, Xavier   Sandbrink, Rupert   Radue, Ernst-Wilhelm   Barkhof, Frederik   Wicklein, Eva-Maria   Kappos, Ludwig   Munger, Kassandra   Ascherio, Alberto   

              Session Name:P5: MS Prognosis/Epidemiology  

              Topic:MS and Inflammatory Disease  

              Program Number:P5.013  

              Author Institution:Harvard T.H. Chan School of Public Health, Boston, MA  Broad Institute of Massachusetts Institute of Technology and Harvard, Boston, MA  CHU Hôpital Pontchaillou, Rennes, France  University of Ottawa, Ottawa, ON, Canada  Heinrich Heine University Medical Faculty Departme, Dusseldorf, Germany  Vall Hebron University Hospital-Multiple Sclerosis Centre of Catalonia, Barcelona, Spain  H. Lundbeck A/S, Valby, Denmark  Medical Image Analysis Center, Basel, Switzerland  Image Analysis Center, Amsterdam, Netherlands  Bayer AG, Berlin, Germany  RC2NB, University Hospital Basel, Basel, Switzerland  Harvard School of Public Health, Boston, MA  

              Infusion-Related Reactions With Ocrelizumab: Risk Factors, Symptom Management and Patient Choices in the ENSEMBLE PLUS Study

              Author:Bermel, Robert   Killestein, Joep   Berger, Thomas   Brochet, Bruno   Carroll, William   Freedman, Mark   Holmoy, Trygve   Karabudak, Rana   Nos, Carlos   Patti, Francesco   Perrin Ross, Amy   Vanopdenbosch, Ludo   Vollmer, Timothy   Buffels, Regine   Kadner, Karen   Bortolami, Oscar   Hartung, Hans-Peter   

              Session Name:P7: MS Therapeutics 1  

              Topic:MS and Inflammatory Disease  

              Program Number:P7.003  

              Author Institution:Mellen Center for MS, Department of Neurology, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, Amsterdam, Netherlands  Department of Neurology, Medical University of Vienna, Vienna, Austria, Vienna, Austria  University of Bordeaux, Bordeaux, France, Bordeaux, France  Department of Neurology, Sir Charles Gairdner Hospital, Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia, Subiaco, Australia  University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, Ottawa, ON, Canada  Department of Neurology, Akershus University Hospital, Lørenskog, Norway, Lasker, Norway  Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey, Ankara, Turkey  Centre d’Esclerosi Mútiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, Barcelona, Spain, Barcelona, Spain  Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Catania, Italy, Catania, Italy  Loyola University Chicago, Chicago, IL, USA , Oak Brook, IL  Department of Neurology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Brugge, Belgium  Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Toulon, France  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Department of Neurology, UKD, Centre of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, Dusseldorf, Germany